3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
28
enzalutamide
23
Specimen Handling
20
apalutamide
17
Androgen Antagonists
14
Radiosurgery
13
Radiotherapy
12
Prednisone
12
Docetaxel
12
Abiraterone Acetate
12
abiraterone
10
Biopsy
10
Radiation
8
niraparib
6
luprolide acetate gel depot
6
darolutamide
6
Pluvicto
6
Leuprolide
6
2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid
6
relugolix
5
gallium 68 PSMA-11
5
cabazitaxel
5
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
5
Nivolumab
5
Gonadotropin-Releasing Hormone
5
bicalutamide
4
Triptorelin Pamoate
4
Surveys and Questionnaires
4
Radiotherapy, Intensity-Modulated
4
Glutamate Carboxypeptidase II
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
rucaparib
×
30 days
×
Clear all
No trials found.